Paul Hudson, CEO of Novartis Pharma AG, discusses pricing, and expectations and dynamics around the company's star products including how Cosentyx (secukinumab) is sitting pretty in the rheumatology and psoriasis space, despite competition. Heart failure drug Entresto (sacubitril/valsartan), which is well on its way internationally, could potentially emerge as one of the most successful medicines ever launched by Novartis in India.
In an exclusive interview with Scrip at Novartis India’s sprawling office in Hyderabad, Hudson also indicated that while there is...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
